2-(4-氨基苯基)-6-甲基[2,6'-联苯并噻唑]-7-磺酸 | 5855-97-0

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-(4-氨基苯基)-6-甲基[2,6'-联苯并噻唑]-7-磺酸
• 中文别名: a1-13-促肾上腺皮质素,N-[4-氯-6-[(3',6'-二羟基-3-羰基螺[异苯并呋喃-1(3H),9'-[9H]占吨]-5-基)氨基]-1,3,5-三嗪-2-基]-4-L-己氨酸-7-D-苯丙氨酸-13-L-缬氨酸酰胺-(9CI)
• 英文名称: 2'-(4-aminophenyl)-6-methyl-[2,6'-bibenzo[d]thiazole]-7-sulfonic acid
• 英文别名: 2'-(4-amino-phenyl)-6-methyl-[2,6']bi[benzothiazolyl]-7-sulfonic acid；2-(4-aminophenyl)-6-methyl(2,6'-bibenzothiazole)-7-sulfonic acid；Primulingelb；Direct Yellow-59 (C.I.)；sulfonated primuline base；primuline；[2,6'-Bibenzothiazole]-7-sulfonic acid, 2'-(4-aminophenyl)-6-methyl-；2-[2-(4-aminophenyl)-1,3-benzothiazol-6-yl]-6-methyl-1,3-benzothiazole-7-sulfonic acid
• CAS: 5855-97-0
• 化学式: C₂₁H₁₅N₃O₃S₃
• 分子量: 453.566
• InChiKey: CTPFWVHDVOKBSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  171
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(4-氨基苯基)-6-甲基[2,6'-联苯并噻唑]-7-磺酸 、 3-(三氟甲基)苯甲酰氯 在 吡啶 作用下， 反应 16.0h， 以54%的产率得到6-methyl-2'-(4-(3-(trifluoromethyl)benzamido)phenyl)-[2,6'-bibenzo[d]thiazole]-7-sulfonic acid
  参考文献：
  名称：

  Optimization of Potent Hepatitis C Virus NS3 Helicase Inhibitors Isolated from the Yellow Dyes Thioflavine S and Primuline

  摘要：

  A screen for hepatitis C virus (HCV) NS3 helicase inhibitors revealed that the commercial dye thioflavine S was the most potent inhibitor of NS3-catalyzed DNA and RNA unwinding in the 827-compound National Cancer Institute Mechanistic Set. Thioflavine S and the related dye primuline were separated here into their pure components, all of which were oligomers of substituted benzothiazoles. The most potent compound (P4), a benzothiazole tetramer, inhibited unwinding >50% at 2 +/- 1 mu M, inhibited the subgenomic HCV replicon at 10 mu M, and was not toxic at 100 mu M. Because P4 also interacted with DNA, more specific analogues were synthesized from the abundant dimeric component of primuline. Some of the 32 analogues prepared retained ability to inhibit HCV helicase but did not appear to interact with DNA. The most potent of these specific helicase inhibitors (compound 17) was active against the replicon and inhibited the helicase more than 50% at 2.6 +/- 1 mu M.

  DOI：

  10.1021/jm300021v

文献信息

• [EN] HCV HELICASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE L'HÉLICASE DU VHC ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV KANSAS

  公开号：WO2013036749A1

  公开（公告）日：2013-03-14

  The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

  本发明揭示了硫黄素S和原黄素衍生物，可抑制丙型肝炎病毒的解旋酶和蛋白酶活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物和治疗HCV感染的方法。
• LIGANDS FOR AGGREGATED TAU MOLECULES
  申请人：Kemp Steven John

  公开号：US20110171739A1

  公开（公告）日：2011-07-14

  Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

  提供了某些苯并噻唑、咪唑噻唑、咪唑嘧啶和咪唑吡啶化合物，包括例如：式（I）和其药学和生理学上可接受的盐、水合物和溶剂化物。这些化合物可用作tau蛋白和PHF的诊断配体或标记。
• HCV Helicase Inhibitors and Methods of Use Thereof
  申请人：Aube Jeffrey

  公开号：US20140227225A1

  公开（公告）日：2014-08-14

  The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

  本发明揭示了硫黄荧光素S和初黄素衍生物，其抑制丙型肝炎病毒的解旋酶和蛋白酶活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，并可用作抗病毒剂。本发明还涉及含有上述化合物的制药组合物和治疗HCV感染的方法。
• US4254026A
  申请人：——

  公开号：US4254026A

  公开（公告）日：1981-03-03
• US4881977A
  申请人：——

  公开号：US4881977A

  公开（公告）日：1989-11-21